trail%2cdr5和pakt在人喉鳞癌中的表达特征及临床病理意义

《trail%2cdr5和pakt在人喉鳞癌中的表达特征及临床病理意义》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号15017中国图书分号R363.2HebeiMedicalUniversity硕士学位论文学术学位TRAIL，DR5和pAKT在人喉鳞癌中的表达特征及临床病理意义研究生：殷晓宁导师：李月红教授范婕教授专业：病理学与病理生理学二级学院：第二医院2018年03月目录中文摘要····························································································1英文摘要·······

2、·····················································································4英文缩写····························································································7研究论文TRAIL,DR5和pAKT在人喉鳞癌中的表达特征及临床病理意义前言···································

3、·························································8材料与方法····························································································10结果····························································································13附图·

4、···························································································15附表····························································································21讨论·································································

5、···························26结论····························································································30参考文献····························································································31综述肿瘤坏死因子相关诱导凋亡配体TRAIL与肿瘤治疗·······

6、··35致谢····························································································45个人简历····························································································46TRAIL,DR5和pAKT在人喉鳞癌中的表达特征及临床病理意义摘要目的：检测人喉鳞状细胞癌组织及喉正常粘膜组织中T

7、RAIL、DR5和pAKT的表达水平，探讨三种蛋白表达与喉鳞状细胞癌患者临床病理特征间的关系，评估三种基因蛋白在喉鳞状细胞癌发生、发展过程中的作用，分析AKT的磷酸化形式在增强喉鳞状细胞癌对TRAIL敏感性过程中的作用机制。方法：应用免疫组织化学染色（Immunohistochemistry,IHC）法分别检测68例喉鳞状细胞癌组织及35例喉正常粘膜组织中TRAIL、DR5和pAKT的表达水平，并结合临床病理特征进行统计学分析。应用SPSS19统计分析软件，统计分析病例之各项指标变化。P<0.05时差异具有

8、统计学意义。结果：1.TRAIL在正常喉粘膜和喉鳞癌组织的表达TRAIL在35例喉正常粘膜组织中阳性率为71.4%（25/35），而68例喉鳞状细胞癌组织中阳性率为39.7%（27/68），两组间比较有明显差异（P<0.05）；在68例喉鳞状细胞癌组织与临床各病理因素的相关性关系中，早期喉癌（ⅠⅠ+期）阳性率为64.3%（9/14）明显高于晚期喉癌（ⅢⅢ+期）33.3%（18/54），两组间比较有明显差异（P<0